MARKET

SUPN

SUPN

Supernus Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

32.23
+0.30
+0.94%
Opening 12:03 06/24 EDT
OPEN
32.26
PREV CLOSE
31.93
HIGH
32.50
LOW
32.10
VOLUME
151.03K
TURNOVER
--
52 WEEK HIGH
34.29
52 WEEK LOW
17.20
MARKET CAP
1.71B
P/E (TTM)
15.59
1D
5D
1M
3M
1Y
5Y
Thinking about buying stock in Fisker, Torchlight Energy, Intec Pharma, Supernus Pharmaceuticals, or Cyclo Therapeutics?
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FSR, TRCH, NTEC, SUPN, and CYTH.
PR Newswire - PRF · 06/17 13:31
Supernus Pharmaceuticals Stock Getting Closer To Key Technical Measure
A Relative Strength Rating upgrade for Supernus Pharmaceuticals shows improving technical performance. Will it continue?
Investor's Business Daily · 06/10 17:21
BRIEF-Supernus Pharmaceuticals Says On May 20, Co Entered Into Commercial Supply Agreement With Catalent Pharma Solutions With Effective Date Of May 12, 2021
reuters.com · 05/26 21:52
BRIEF-Supernus Pharmaceuticals Says On May 24, Co & Newron Pharmaceuticals Received A Paragraph IV Notice Letter From Rk Pharma
reuters.com · 05/25 23:29
Supernus to Present at Jefferies Virtual Healthcare Conference
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Supernus Pharm...
GlobeNewswire · 05/25 12:30
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
Qelbree™ has proven efficacy in ADHD, with improvement in symptoms as early as the first weekROCKVILLE, Md., May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializi...
GlobeNewswire · 05/24 12:30
Supernus Pharmaceuticals Says Co. And Newron Received Notice Letters From MSN Laboratories, Optimus Pharma And Zenara Pharma Advising Supernus Of Filings Of Abbreviated NDAs To FDA Seeking Approval Of Mesylate Tablets
On each of May 14, 2021, May 15, 2021 and May 17, 2021, Supernus Pharmaceuticals, Inc. (the “Company”) and Newron Pharmaceuticals S.p.A. (“Newron”) received Paragraph IV Notice Letters
Benzinga · 05/19 20:16
10-Q: SUPERNUS PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management's Discussion and...
Edgar Online - (EDG = 10Q, 10K) · 05/07 20:55
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SUPN. Analyze the recent business situations of Supernus Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SUPN stock price target is 35.00 with a high estimate of 40.00 and a low estimate of 30.00.
EPS
Institutional Holdings
Institutions: 387
Institutional Holdings: 63.06M
% Owned: 118.94%
Shares Outstanding: 53.02M
TypeInstitutionsShares
Increased
75
2.77M
New
33
2.35M
Decreased
73
3.15M
Sold Out
31
1.19M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Independent Director
Charles Newhall
President/Chief Executive Officer/Secretary/Director
Jack Khattar
Chief Financial Officer/Executive Vice President
James Kelly
Senior Vice President/Chief Scientific Officer
Padmanabh Bhatt
Senior Vice President
Tami Martin
Senior Vice President
Frank Mottola
Senior Vice President
Jonathan Rubin
Independent Director
Carrolee Barlow
Independent Director
Frederick Hudson
No Data
  • All
  • Financials
  • Insiders
More
About SUPN
Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Webull offers kinds of Supernus Pharmaceuticals Inc stock information, including NASDAQ:SUPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SUPN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SUPN stock methods without spending real money on the virtual paper trading platform.